|
|
|
06.10.25 - 10:45
|
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency (GlobeNewswire EN)
|
|
|
LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair® (omalizumab)....
|
|
|
06.10.25 - 10:42
|
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency (GlobeNewswire EN)
|
|
|
LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair® (omalizumab)....
|
|
|
03.10.25 - 11:00
|
ANLEIHEN-Woche #KW40 – 2025: UBM, Eleving, reconcept, PCC, The Platform Group, Mutares, ABO Energy, Katjes Greenfood, PNE, Dautrus, The Grounds, Energiekontor, LEEF, WeGrow, Formycon, ESPG, Pferdewetten, … (Anleihen-Finder)
|
|
|
ANLEIHEN-Woche #KW40 – 2025: UBM, Eleving, reconcept, PCC, The Platform Group, Mutares, ABO Energy, Katjes Greenfood, PNE, Dautrus, The Grounds, Energiekontor, LEEF, WeGrow, Formycon, ESPG, Pferdewetten, ...
Der Beitrag ANLEIHEN-Woche #KW40 – 2025: UBM, Eleving, reconcept, PCC, The Platform Group, Mutares, ABO Energy, Katjes Greenfood, PNE, Dautrus, The Grounds, Energiekontor, LEEF, WeGrow, Formycon, ESPG, Pferdewetten, … erschien zuerst auf Anleihen-Finder.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.09.25 - 12:21
|
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech′s Proposed Biosimilar to Prolia® and Xgeva® (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for AVT03, Alvotech's proposed biosimilar to Prolia® (denosumab 60 mg/mL single use pre-filed syringe) and Xgeva® (denosumab 70 mg/mL single use vial). Pending approval, the biosimilar will be marketed by Alvotech's commercial partners, STADA Arzneimittel AG (“STADA”) and Dr. Reddy's Laboratories SA (“Dr. Reddy's”), each partner with semi-exclusive commercial rights in Europe, including Switzerland and the UK....
|
|
|
22.09.25 - 12:18
|
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech′s Proposed Biosimilar to Prolia® and Xgeva® (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for AVT03, Alvotech's proposed biosimilar to Prolia® (denosumab 60 mg/mL single use pre-filed syringe) and Xgeva® (denosumab 70 mg/mL single use vial). Pending approval, the biosimilar will be marketed by Alvotech's commercial partners, STADA Arzneimittel AG (“STADA”) and Dr. Reddy's Laboratories SA (“Dr. Reddy's”), each partner with semi-exclusive commercial rights in Europe, including Switzerland and the UK....
|
|
|
22.09.25 - 10:36
|
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech′s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for Gobivaz®, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases....
|
|
|
|
|
19.09.25 - 13:51
|
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark® (denosumab), AVT05, a biosimilar to Simponi® (golimumab) and AVT06, a biosimilar to Eylea® (aflibercept). Based on publicly available information, AVT05 is the first golimumab biosimilar to be approved for sale in major markets globally....
|
|
|
19.09.25 - 13:48
|
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark® (denosumab), AVT05, a biosimilar to Simponi® (golimumab) and AVT06, a biosimilar to Eylea® (aflibercept). Based on publicly available information, AVT05 is the first golimumab biosimilar to be approved for sale in major markets globally....
|
|
|
|
|
04.09.25 - 15:21
|
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET)....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
